Abstract
ABSTRACT
Endoscopic ultrasound‐guided biliary drainage (EUS‐BD) is used when biliary drainage using endoscopic retrograde cholangiopancreatography fails. Recently, it has been adopted as a primary biliary drainage method, and its indications have expanded. Since EUS‐BD can cause adverse events (AEs), such as bile leakage and stent migration, which do not occur in endoscopic retrograde cholangiopancreatography, endoscopists need to be well‐versed in its management and preventive techniques. EUS‐BD includes several procedures, such as EUS‐guided choledochoduodenostomy (EUS‐CDS), EUS‐guided hepaticogastrostomy (EUS‐HGS), EUS‐guided antegrade stenting (EUS‐AS), and EUS‐guided rendezvous (EUS‐RV). A recent meta‐analysis reported that the overall AE rate of EUS‐BD was 13.7% (EUS‐CDS, 11.9%; EUS‐HGS, 15.5%; EUS‐AS, 9.9%; and EUS‐RV, 8.8%). Among various EUS‐BD techniques, EUS‐CDS and EUS‐HGS are the most frequently reported. Tubular self‐expandable metal stents have been traditionally used in EUS‐CDS; however, lumen‐apposing metal stents have recently gained popularity. A systematic review showed that the rates of early AEs were similar between self‐expandable metal stents and lumen‐apposing metal stents; however, stent maldeployment was more problematic with lumen‐apposing metal stents. Although tubular self‐expandable metal stents are used in EUS‐HGS, stent maldeployment remains a serious issue, and available devices and technical tips for preventing this AE should be well understood. Furthermore, AEs, such as sepsis, cholangitis, and bleeding, can occur, and strategies to mitigate these risks are essential. In this narrative review, we discussed AEs related to EUS‐BD with a focus on management options and strategies for prevention.